Related references
Note: Only part of the references are listed.Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with 18F-Fluoroazomycin Arabinoside and 15O-H2O PET
Ramsha Iqbal et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice
Paul Slobbe et al.
EJNMMI RESEARCH (2015)
Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [11C]erlotinib PET
Galith Abourbeh et al.
EJNMMI RESEARCH (2015)
Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care
Lemonitsa H. Mammatas et al.
CELLULAR ONCOLOGY (2015)
Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care
Nienke A. G. Lankheet et al.
THERAPEUTIC DRUG MONITORING (2014)
EGFR mutation positive stage IV non-small-cell lung cancer: treatment beyond progression
Katrijn Van Assche et al.
FRONTIERS IN ONCOLOGY (2014)
Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status
Idris Bahce et al.
CLINICAL CANCER RESEARCH (2013)
EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
Maria E. Arcila et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Quantitative Analysis of [11C]-Erlotinib PET Demonstrates Specific Binding for Activating Mutations of the EGFR Kinase Domain
J. Ryan Petrulli et al.
NEOPLASIA (2013)
PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer
A. A. Memon et al.
BRITISH JOURNAL OF CANCER (2011)
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
Vicki Leigh Keedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor
Britta Weber et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Good Clinical Response to Gefitinib in a Non-small Cell Lung Cancer Patient Harboring a Rare Somatic Epidermal Growth Factor Gene Point Mutation; Codon 768 AGC > ATC in Exon 20 (S768I)
Katsuhiro Masago et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Quantitative Parametric Perfusion Images Using 15O-Labeled Water and a Clinical PET/CT Scanner: Test-Retest Variability in Lung Cancer
Astrid A. M. van der Veldt et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
Jenn-Yu Wu et al.
CLINICAL CANCER RESEARCH (2008)
Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression
Hui Wang et al.
CANCER SCIENCE (2007)
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
Jing Li et al.
CLINICAL CANCER RESEARCH (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Update on epidermal growth factor receptor mutations in non-small cell lung cancer
Gregory J. Riely et al.
CLINICAL CANCER RESEARCH (2006)
PET kinetic analysis - compartmental model
Hiroshi Watabe et al.
ANNALS OF NUCLEAR MEDICINE (2006)
Positron emission tomography compartmental models
RN Gunn et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2001)
Share Paper
